MedTrace Logo

ALLOPURINOL AND LISINOPRIL FOR DIABETIC KIDNEY PROTECTION: A COMPARATIVE STUDY IN NORMOURICEMIC TYPE 2 DIABETICS

NCT07177898 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-09-17

No results posted yet for this study

Summary

This randomized controlled trial was conducted at the Department of Medicine and Diabetes of Mayo Hospital/King Edward Medical University, Lahore, over one year. A total of 80 patients with type 2 diabetes and normal serum uric acid were randomly assigned to two groups: Group A received allopurinol with lisinopril, and Group B received lisinopril alone. Patients were monitored every three months for serum creatinine, spot urine albumin, and serum uric acid levels. The primary endpoint was a \>300 mg/L increase in urine albumin from baseline. Blood pressure was managed with agents other than ACE inhibitors if required.

Conditions

  • Diabetic Kidney Disease (DKD)

Interventions

DRUG

Allopurinol

Group A received allopurinol with lisinopril, and Group B received lisinopril alone

Sponsors & Collaborators

  • King Edward Medical University

    collaborator OTHER

  • Narowal Medical College

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-14
Primary Completion
2024-09-23
Completion
2024-11-18

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07177898 on ClinicalTrials.gov